Amedica, a full-line manufacturer and supplier of silicon nitride technologies that are used in spinal implant applications, has developed unique SiN materials having disruptive characteristics for spinal, hip and knee implant applications. The material is remarkably fracture resistant, and its articulating surfaces do not produce the wear debris that is linked to osteolysis-related re-operations. Additionally, the Bioactive implants provide a hydrophilic surface and a conductive cancellous structure that enhances bone ingrowth and attachment.
The company recently entered into a Joint Venture Agreement with Orthopaedic Synergies Inc., a global reconstructive hip and knee concern known for its innovative and new implant technologies, expanding its reach into a more widespread orthopaedic marketplace.
"This latest patent for expanded use of our monoblock silicon nitride technology further marks a notable milestone in orthopaedic implants and other related applications," Shappley notes. "It also further secures Amedica's future competitive position in the reconstructive implant segment, which is one of the largest and rapidly-growing segments in the industry."
Amedica Corporation is ISO 13485 certified and its products are FDA cleared and CE approved. Amedica Corporation is an emerging orthopaedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, unique spine and total joint implants for the growing orthopaedic device market. It has brought to market various spinal implant products, while products under development include reconstructive hip and knee implants that represent a new
|SOURCE Amedica Corporation|
Copyright©2010 PR Newswire.
All rights reserved